1 Therapies|Clear filters
Reg. name: Darzalex®
Class: Monoclonal Antibody
Daratumumab is a humanized monoclonal antibody against the human protein CD38, which is highly expressed on Multiple Myeloma cells. Binding of CD38 by daratumumab stimulates apoptosis directly via Fc-mediated crosslinking. In addition, daratumumab stimulates antibody dependent cell mediated cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) of target cells. Due to expression of CD38 on a subset of myeloid derived suppressor cells (MDSCs), regulatory T cells (CD38+Tregs) and B cells (CD38+Bregs), these are also decreased by daratumumab.
DARZALEX® is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
|Disease:||Patients eligible for transplant, Patients non-eligible for transplant, Relapsed/refractory patients, General MM,|
DARZALEX® as monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
|Disease:||Relapsed/refractory patients, Elderly patients, General MM,|